REGENERON PHARMACEUTICALS, INC. (REGN)
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
BANCO SANTANDER S.A. (SAN)
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse
KULICKE & SOFFA INDUSTRIES INC (KLIC)
Kulicke & Soffa Launches ASTERION™‑TW: Innovative Ultrasonic System Expands Power Assembly Portfolio
YIMUTIAN INC. (YMT)
Yimutian Inc. to Acquire Ningbo Xunxi Technology for RMB 50 Million, Entering the Enterprise Digital Commerce Market
APOLLO GLOBAL MANAGEMENT, INC. (APO)
Apollo Funds Announce Strategic Investment in NSG Group, a Global Leader in Glass Manufacturing
BOSTON SCIENTIFIC CORP (BSX)
Robbins LLP Urges BSX Stockholders Who Lost Money Investing in Boston Scientific Corporation to Contact the Firm for Information About Leading the Class Action
AQUESTIVE THERAPEUTICS, INC. (AQST)
Robbins LLP Urges AQST Stockholders Who Lost Money Investing in Aquestive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action
EOS ENERGY ENTERPRISES, INC. (EOSE)
Robbins LLP Urges EOSE Stockholders Who Lost Money Investing in Eos Energy Enterprises, Inc. to Contact the Firm for Information About Leading the Class Action
DRIVEN BRANDS HOLDINGS INC. (DRVN)
Robbins LLP Urges DRVN Stockholders Who Lost Money Investing in Driven Brands Holdings Inc. to Contact the Firm for Information About Leading the Class Action
SOLENO THERAPEUTICS INC (SLNO)
Robbins LLP Urges SLNO Stockholders Who Lost Money Investing in Soleno Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action